The governance of agro- and pharmaceutical biotechnology innovation: Public policy and industrial strategy

Multinational companies in the life science sector are heavily influenced by government policies and regulations and in turn attempt to influence these actors nationally and internationally. This paper focuses on recent and on-going research, principally on the agro-biotechnology and, to a lesser extent, on the pharmaceutical industries, covering the evolution of policy and regulation in Europe, how policies are influenced by stakeholder pressures and how policy in turn influences company strategies for product development. We focus particularly on new ‘governance’ agendas in Europe and consider the relative impacts of enabling, constraining, discriminating and indiscriminate policies on company strategies as part of our development of an integrated approach to policy and governance. We also consider changes in external operating environments for multinational companies and compare past histories and present pressures on agro-biotechnology and pharmaceutical companies. The paper argues, with evidence, that a more enabling and discriminating policy and regulatory environment can achieve public goals more efficiently and effectively, taking account of impacts on innovation, than more blunt policy instruments. This type of environment takes into account the resources and capabilities available to firms and research laboratories rather than relying on broad brush carrot and stick approaches.     

基于产业链的自主创新的政策支撑体系研究

科技和创新是经济发展的关键,建设创新型国家是提升国家竞争力的重大战略决策.本文以产业经济学、创新管理理论为指导,在梳理各项自主创新政策在产业链上的作用机理后进行了实证,得出政府应在构建产业创新系统的基础上选择重点产业、根据上下游关系制定相关政策、加大对产业链上关键技术和核心技术政策支持力度、以重大产品开发为龙头带动整体自主创新的政策建议.     

Clusters,industrial policy and firm strategy

Increasingly, govemments and firms take clusters of related business as a starting point to formulate policies and strategies, which aim at enhancing innovation. There appear, however, to be quite some different conceptions of what clusters are, In the first part of this paper and attempt is made to clarify the cluster concept by defining the relevant dimensions of clusters. In the second part, each of these dimensions is related to possible industrial policies and firm strategies. Practical illustrations will be given from different European countries and firms. The dimensions and related policies and strategies form a menu of possibilities from which actors can choose those elements that are most relevant for their specific situation. Thus, tailor-made policies and strategies can be devised and implemented.     

Clusters, industrial policy and firm strategy

Increasingly, govemments and firms take clusters of related business as a starting point to formulate policies and strategies, which aim at enhancing innovation. There appear, however, to be quite some different conceptions of what clusters are, In the first part of this paper and attempt is made to clarify the cluster concept by defining the relevant dimensions of clusters. In the second part, each of these dimensions is related to possible industrial policies and firm strategies. Practical illustrations will be given from different European countries and firms. The dimensions and related policies and strategies form a menu of possibilities from which actors can choose those elements that are most relevant for their specific situation. Thus, tailor-made policies and strategies can be devised and implemented.     

The limits of policy: Public acceptance and the reform of science and technology governance

The adoption of a variety of new regulatory approaches and concepts, decision making processes and educational frames over the last three decades can be interpreted as an attempt to improve social acceptability of the process of science and technology governance. However, as argued in this paper, neither the introduction of non-standard scientific methodology and precautionary policy, nor participatory decision making, nor increased scientific-technological education are likely to significantly improve social acceptance of science and technology governance. Such reforms may shift the focus of ongoing policy debates, but do not lead to closure. In consequence, more research is needed on the complex relationship between acceptance, trust, information and participation, the implications of non-standard methodology in regulatory decision making, as well as the different interpretations that stakeholders may give to key regulatory concepts.     

Competition policy vs. industrial policy as a growth strategy

ABSTRACT

This paper shows that competition policy, rather than industrial policy, generated the rapid economic growth in post-war Japan. It also reveals that Japan’s growth rate was lowered from the mid-1970s due to newly introduced industrial policies and paucity of further competition policy. The current Abe government recognises the need for competition policies in Japan to recover from the low-growth period. The paper describes the types of competition policy carried out under Abenomics, especially in National Strategic Special Zones.Abbreviations: METI: Ministry of Economy, Trade, and Industry NSSZ: National Strategic Special Zones     

Technology import,secondary innovation,and industrial structure optimization: A potential innovation strategy for China

To enhance people’s lives, China needs to maximize the opportunities of technological changes and conduct innovations to optimize its industrial structure in the context of intellectual property rights (IPR) protection. The present paper analyses how industrial structure can be optimized by considering technology imports and innovations, and proposes an innovation strategy for China. We decompose imported technology into embodied technology imports (ETI) and disembodied technology imports (DTI). We found that ETI and DTI have negative effects on industrial structure rationalization and supererogation. Moreover, secondary innovations based on ETI depress industrial rationalization and supererogation, while secondary innovations based on DTI contribute positively. Therefore, DTI should be valued and the absorption of introduced technology improved. It is important to choose the appropriate mode of technology imports, to coordinate on the ratio of technology imports to secondary innovations, and to enhance the absorption of imported technology with the gradual improvement of IPR protection.     

Pursuing a biotechnology system of innovation in Lithuania: a conceptual framework for effective policy intervention

The focus of this paper is on Lithuania, whose government released an ambitious innovation strategy to become an innovative services hub for Northern Europe by 2015, and an innovation hub by 2020. Biotechnology has been identified as a strategic sector, and whether Lithuania will be able to achieve its ambition of a fully functioning biotechnology sectoral system of innovation will be explored. With the Lithuanian government declaring that they will intervene to achieve their innovation goals, this paper argues that sound policy intervention is possible and can be done in a way that avoids the limitations of past systemic approaches. The policy approach presented is based on a modified extended industry life cycle, and the movement of system structures through three phases – background, pre-emergence and emergence – and explains how each phase lays the groundwork for transition to the next phase.     

Open innovation and intellectual property strategy: the catch-up processes of two Chinese pharmaceutical firms

We explore the interaction of open innovation and intellectual property (IP) in two Chinese latecomer pharmaceutical firms in their catch-up process. Studying archival data, documentation, and interviews, we found that the two firms exhibited five periods that were characterised by different open innovation activities and R&D capabilities. In their early stages, the two firms lacked R&D functions; thus, they imported technologies and pursued production-oriented strategies. As they gradually entered into collaborations and established their R&D departments, open innovation and IP protection played important and dynamic roles in this process. Thus, a catch-up process involves not only acquiring technological capabilities and innovative competencies but also transforming a firm's capacity to strategies.     

The trade-off between innovation and defense industrial policy: A simulation model analysis of the Norwegian defense industry

The paper investigates the trade-off between innovation and defense industrial policy. It presents an agent-based simulation model calibrated for the Norwegian defense industry that compares different policy scenarios and examines the effects of a pending EU market liberalization process. The paper points to two main results. (1) It finds that a pure scenario where national authorities focus on, and provide support exclusively for, either a) international competitiveness or b) national defense and security objectives, is more Pareto efficient than a corresponding mixed strategy where policy makers simultaneously pursue both international competitiveness and defense and security objectives. (2) Under the conditions of the new EU liberalization regime, it finds that a stronger and more visible trade-off will emerge between international competitiveness and national defense and security objectives. Policy makers will have to choose which to prioritize, and set a clear agenda focusing on one of the two objectives.     

How technological innovation affects the structure of an industry: entrepreneurship evolution in the biotechnology and pharmaceutical industry since 1980

Challenges faced by the biotechnology and pharmaceutical industry, including reduced R&D productivity and the expiration of drugs that are high in demand, are recently being addressed through technological innovation. Such innovations are highly likely to change the structure and functioning of the industry. Since 2000, biotechnology and pharmaceutical companies have actively made strategic alliance, and technological innovations have changed the source of innovation from R&D to entrepreneurship within the industry. In this study, we identify the evolution of entrepreneurship and discuss the changes caused by technological advancements since 1980 by analysing patterns of exporting and acquiring technology data from Medtrack. Over difference period, biopharmaceutical firms have gained new knowledge and improved technology, and have implemented this newly acquired knowledge and innovation to introduce drugs to the market.     

The evolution and performance of biotechnology regional systems of innovation

The paper maintains that biotechnology regions develop as complexsystems: they start with star scientists in research universities,generating knowledge spillovers, then move progressively towardsregional technology markets. In the process they attract venturecapital (or modify the behaviour of existing venture capitalfirms with the addition of biotechnology portfolios). The routinesof universities are also modified with the addition of intellectualproperty and technology transfer offices intervening as sellersin the newly created knowledge markets. The paper also considerswhether companies located in regional agglomerations grow fasterthan isolated ones, and whether companies spun-off from universitieshave a better performance than start-ups. The study is basedon about 90 Canadian-based publicly quoted biotechnology companies.     

The pharmaceutical industry: Towards a new innovation environment

This article examines one facet of changing research alliances between the private and public sector. Consideration ofthe changes occurring within the pharmaceutical industry as a whole and its approach to research and development (R&D) give us some indight into why pharmaceutical companies are are zncreasingly choosing to embark on long-term R&D collaborations with hzgher education establishments. The article suggests possible future directions of alliances and raises questions regarding the implications for industrial and academic research departments izs a result of such collaborations.     

The choice of innovation policy instruments

The purpose of this article is to discuss the different types of instruments of innovation policy, to examine how governments and public agencies in different countries and different times have used these instruments differently, to explore the political nature of instrument choice and design (and associated issues), and to elaborate a set of criteria for the selection and design of the instruments in relation to the formulation of innovation policy. The article argues that innovation policy instruments must be designed and combined into mixes in ways that address the problems of the innovation system. These mixes are often called “policy mix”. The problem-oriented nature of the design of instrument mixes is what makes innovation policy instruments ‘systemic’.     

Management of agriculture-related biotechnology constraints on innovation

This paper outlines constraints on jrms operating in the area of agriculture and, food-related biotechnology. It reports on findings from a study involving ouer 60 interviews with managers in firms innocating in this area. Cognitive maps are used to explore issues in the management of the technology, and depict various approaches adopted. It highlights market and organizational constraints, and discusses differences in large and smalljinns. The paper concludes that small dedicated biotechnology firms are disadvantaged in a number of important ways in this field of innovation. However, large multinational corporations also experience market and o~qanizational difficulties.     

Relating business model innovations and innovation cascades: the case of biotechnology

This article conceptualizes innovation as a process, where the scientific and industrial application of technological knowledge nurtures new routines and institutions, in order to relate changing business model innovations to innovation cascades. Innovation in science-based, high-tech sectors is changing its tempo, from the evolutionary pace of incremental novelties punctuated by occasional radical novelties, to innovation cascades. These cascades involve a long series of interlinked radical innovations, which can be traced through various scientific and technological indicators like patents and publications. Innovation cascades are relevant to industry, because they make the future less predictable. They are particularly interesting because these changes also enable the testing an abundance of new business models. Innovation cascades have a major impact on the number and sustainability of business models and on strategy. Business model innovations are visible not only in the existing organizations that undergo change, but also new organizational models appear. The case of biotechnology after the 1980s is used to illustrate our conceptualization.     

Ownership structure,governance, and innovation

This paper tests the impact of firms׳ ownership structure on innovation in a context featuring pronounced ownership concentration and conflicts between large and minority shareholders. Using data for 20,000 Italian manufacturers, and accounting for the possible endogeneity of ownership levels, we find that ownership concentration negatively affects innovation, especially by reducing R&D effort. Conflicts between large and minority shareholders appear to be a determinant of this effect. Moreover, risk aversion induced by lack of diversification exacerbates large shareholders׳ reluctance to innovate. Family owners support innovation more than financial institutions, but the benefits of financial institutions increase with their equity stakes.     

The effects of patent-law changes on innovation: The case of India's pharmaceutical industry

Recent patent-law changes in India's pharmaceutical industry provide opportunities to study changes of institutional and regulatory environments on innovation and social welfare in low-income markets. From 1972 to 2004 under its process-patent regime, India's pharmaceutical industry grew to become the world's fourth largest. Indian companies were becoming globally competitive in generics and clinical testing, and moving into product R&D. Researchers have debated the effects of India's new product-patent laws' effects on these trends. The authors cover the domestic characteristics and global competitiveness of India's pharmaceutical industry. They contrast data (from 2001 to 2004) on patents in India's process-patent regime with preliminary data (from 2005 to 2008) on patents in the country's new product-patent regime. They argue that Indian pharmaceutical companies have changed their decision-making in response to changed patent laws by moving from process to product research. However, the preliminary results indicate that these changes may have hurt domestic innovation. They conclude with strategic implications for the Indian pharmaceutical industry and highlight the need for research and public policy to establish optimal social returns from product-patent regimes.